By Marie Rosenthal, MS
In a unanimous vote, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus vaccines to adults 50 to 59 years of age at increased risk for RSV-associated lower respiratory tract disease (LRTD).
This includes people with conditions such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, cardiovascular disease and those in residential care. This new recommendation